The Technical Analyst
Aptevo Therapeutics Inc [APVO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aptevo Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-7.35% $0.783
America/New_York / 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.527 mill |
| EPS: | -67.07 |
| P/E: | -0.0100 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 0.673 mill |
| Avg Daily Volume: | 0.229 mill |
| RATING 2024-04-15 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0100 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0800 - 1.646 ( +/- 110.22%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-04 | Taylor Daphne | Buy | 1 584 | Common Stock |
| 2024-03-02 | Taylor Daphne | Buy | 3 667 | Common Stock |
| 2024-03-02 | Taylor Daphne | Sell | 3 667 | Restricted Stock Unit |
| 2024-03-04 | Taylor Daphne | Sell | 1 584 | Restricted Stock Unit |
| 2024-03-03 | Lamothe Jeffrey G. | Buy | 3 667 | Common Stock |
| INSIDER POWER |
|---|
| 28.45 |
| Last 99 transactions |
| Buy: 423 660 | Sell: 158 934 |
Forecast:
16:00 - $0.780
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.780
Forecast 2: 16:00 - $0.780
Forecast 3: 16:00 - $0.780
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.783 (-7.35% ) |
| Volume | 0.460 mill |
| Avg. Vol. | 0.229 mill |
| % of Avg. Vol | 200.90 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APVO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
APVO
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Last 10 Buy Signals
Latest Press Releases
2024-04-15 16:05:00 - Press Release
Aptevo Therapeutics Announces Closing Of $4.6 Million Public Offering
Seattle, wa / accesswire / april 15, 2024 / aptevo therapeutics inc. (nasdaq:apvo), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary adaptir™ and adaptir-flex™ platform technologies, today announced the closing of its previously announced public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the "common warrants") at a purchase price of $1.35 per share and associated common warrant. each share of common stock is being offered together with two common warrants, each to purchase one share of common stock.
2024-04-11 08:00:00 - Press Release
Aptevo Therapeutics Announces Pricing Of $4.6 Million Public Offering
Seattle, wa / accesswire / april 11, 2024 / aptevo therapeutics inc. (nasdaq:apvo), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary adaptir™ and adaptir-flex™ platform technologies, today announced the pricing of a public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the "common warrants") at a purchase price of $1.35 per share and associated common warrant. each share of common stock is being offered together with two common warrants, each to purchase one share of common stock.
2024-04-10 09:00:00 - Press Release
Aptevo Therapeutics Provides Pipeline Update
Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the potential for greater clinical benefit in the alg.apv-527 clinical trial cohort 5 dosing imminent, trial more than 50% enrolled apvo436 phase 1b/2 dose optimization trial initiation expected 1h 2024 premier cro, prometrika, engaged as partner for dose optimization trial to evaluate apvo436 in frontline aml in combination with venetoclax + azacitidine in venetoclax naÏve patients apvo711 demonstrates its ability to induce tumor killing properties in preclinical studies apvo711 dual mechanism checkpoint inhibitor with unique precision targeting capabilities progressing towards ind seattle, wa / accesswire / april 10, 2024 / aptevo therapeutics inc...
2024-03-18 06:00:00 - Press Release
Aptevo Participating In The Springtime Partnering Event, A Bio-europe Conference
Seattle, wa / accesswire / march 18, 2024 / aptevo therapeutics inc. (nasdaq:apvo), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary adaptir™ and adaptir-flex™ platform technologies, today announced that the company is participating in the springtime event, a bio-europe conference occurring march 18-20, 2024 in barcelona, spain. the conference, which brings together almost 4,000 attendees, facilitates relationship building and meetings between and among companies across the biotechnology and biopharmaceutical industries.
2024-03-05 08:05:00 - Press Release
Aptevo Therapeutics Reports 2023 Financial Results And Provides A Business Update
Announces 1h24 plan for development of lead candidate apvo436 for the treatment of frontline acute myeloid leukemia, interim results expected late 2h24 alg.apv-527 phase 1 trial for the treatment of multiple solid tumors continues enrollment, interim results expected 1h24 seattle, wa / accesswire / march 5, 2024 / aptevo therapeutics inc. (nasdaq:apvo), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary adaptir™ and adaptir-flex™ platform technologies, today reported financial results for the year ended december 31, 2023 and provided a business update. business update apvo436 apvo436, aptevo's cd3 x cd123 bispecific, is currently in clinical development for the treatment of acute myeloid leukemia (aml), of which there are approximately 20,000 new diagnoses and 11,000 deaths annually in 2023, the company concluded a multi-center, multi-cohort dose expansion study.
Latest News
2024-04-11 08:15:41 - InvestorPlace
Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today?
Aptevo Therapeutics (NASDAQ: APVO ) stock is falling on Thursday after the clinical-stage biotechnology company priced a public offering for its shares. That public offering has Aptevo Therapeutics selling 3.4 million shares of APVO stock at a price of $1.35 each.
2023-11-01 07:45:00 - Accesswire
Aptevo to Present at Bio-Europe Conference
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company will present at the upcoming Bio-Europe conference occurring November 6-8, 2023 in Munich, Germany. Details of the Company's presentation, which will highlight its pipeline of clinical and pre-clinical bispecific drug candidates designed to fight both solid and hematologic malignancies, are as follows: Date & Time: Tuesday, November 7, 2023 @ 1:15 CET (8:15 Eastern time) Location: Trade Fair Center Messe München, San Sabastian Room, Munich, Germany Presenter: Michelle Nelson, Ph...
2023-07-30 14:17:20 - InvestorPlace
7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes
Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poor.
2023-03-03 18:57:06 - InvestorPlace
The Top 7 Growth Stocks in Biotech
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
2022-03-24 14:59:02 - Benzinga
Why Did Aptevo Therapeutics Stock Jump 25% Today?
Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher Thursday after the company reported 2021 financial results. Aptevo said royalty revenue totaled $12.3 million in 2021, up from royalties of $4.3 million in 2020.
2022-02-09 14:28:22 - Benzinga
Why Are Aptevo Therapeutics Shares Trading Higher Today?
Aptevo Therapeutics Inc APVO earned a $10 million non-dilutive milestone payment related to 2021 sales of Ruxience, under the terms of its royalty purchase agreement with HealthCare Royalty Management LLC. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
2021-11-23 10:50:20 - Schaeffers Research
Healthcare Stock Soars on Cancer Treatment Update
The shares of Aptevo Therapeutics Inc (NASDAQ:APVO) are soaring today, up 35% to trade at $8.75 at last check, after the biotech concern announced that one high-risk cancer patient had a complete remission after being treated with its experimental drug, APVO436, combined with chemotherapy.
2021-11-23 10:18:43 - Pulse2
Aptevo Therapeutics (APVO) Stock: Why The Price Surged Today
The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) increased by over 40% during intraday trading today. This is why it happened.
2021-10-27 08:05:00 - Accesswire
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, will participate at the 2nd Virtual Congress on Controversies in Leukemias (EuroLeuk), an international leukemia symposium which is being held October 28-29, 2021, with a Poster Presentation. The poster abstract was selected as one of the best abstracts and included into the Congress program as an oral presentation as well.
2021-09-28 08:05:00 - Accesswire
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for targeting both MDS clones and immunosuppressive myeloid-derived suppressor cells in high-risk adult MDS patients SEATTLE, WA / ACCESSWIRE / September 28, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the prestigious medical journal Frontiers in Aging, published a peer-reviewed article by Fatih Uckun, M...